CEO message


Dear customers, partners, and colleagues, 

As the year draws to a close, I would like to thank you for your dedication and hard work throughout 2022.  I am always impressed by the tremendous efforts you all make to ensure we contribute to the acceleration of clinical trials and drug development.

This has been a significant year for our Novotech team as we expanded our clinical operations beyond our strong foundations in Asia Pacific, to the United States where many of our biotech customers are based. This expansion was driven by customer demand, particularly those pursuing later phase global studies. I am delighted with the extremely positive feedback and progress we have achieved so far. 

Our significant Asia Pacific presence and local expertise has been built up over almost three decades and continues to attract global biotechs wanting access to large patient populations, as well as leading medical institutions and investigators. Our clients are always impressed with the local expertise and experience of our people and our deep understanding of the needs of biotech clients. 

2022 has also been a year we have invested heavily in leading edge systems and infrastructure, and we are already seeing significant improvements in key speed and quality metrics that our customers value.

Novotech now employs over 2,500 people across the Asia-Pacific region and the US. The work that our people do impacts millions of people around the world, and we remain highly committed to creating an exceptional workplace. 

In 2022, Novotech received a number of significant awards including CenterWatch Top 10 Global CRO awards, Asia Pacific CRO Company of the Year from Frost & Sullivan, and the Cell & Gene Therapy Excellence Award – Clinical Trials Asia Pacific. 

Importantly we were recognised with new workplace culture and gender equality awards across the countries in which we operate. We continue to be dedicated to improving our working environment and enhancing employee health and wellbeing. 

We look forward to supporting the clinical research industry in the discovery of new medicines and vaccines into 2023 and we wish you all a safe and enjoyable time with loved ones over the holiday period. 


John Moller